By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Allergan Inc. 

2525 Dupont Drive

Irvine  California  92612  U.S.A.
Phone: 714-246-4500 Fax: n/a


SEARCH JOBS

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have approximately 11,100 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. For the year ending 2012, our total product net sales totaled $5.5 billion, a 10 percent increase over 2011. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate more than six decades of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com.


Key Statistics


Email: Corpinfo@allergan.com
Ownership: Public

Web Site: Allergan Inc.
Employees: 11,100
Symbol: AGN
 



Industry
Pharmaceutical


Collaborations

Elan Pharmaceuticals 

CeNes Pharmaceuticals (U.S.) 

PanVera LLC 

Pharmagene Laboratories Limited  Phase ZERO(TM) products and services.

ACADIA Pharmaceuticals, Inc.  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

ACADIA Pharmaceuticals, Inc.  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

ACADIA Pharmaceuticals, Inc.  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.





Company News
Allergan Inc. (AGN) Quietly Leases A 90,000 Square Feet Space In Texas 10/1/2014 7:20:14 AM
If Allergan Inc. (AGN) Survives Valeant (VRX), AbbVie (ABBV)/Shire or Actavis (ACT)/Forest May Be Suitors 9/30/2014 3:50:01 PM
Analysts Say Valeant Pharmaceuticals International (VRX)/Allergan Inc. (AGN) Deal Could Lead To Buying Spree 9/29/2014 3:30:37 PM
Allergan Inc. (AGN) Board Of Directors Issues Statement 9/29/2014 12:50:13 PM
Allergan Inc. (AGN) Announces FDA Approves Revised Indication For OZURDEX ® (Dexamethasone Intravitreal Implant) 0.7 Mg For The Treatment Of Diabetic Macular Edema 9/29/2014 11:34:54 AM
Pentwater Capital Management Issues Letter To Board Of Directors Of Allergan Inc. (AGN) 9/26/2014 10:03:39 AM
Valueact Places CEO On Valeant Pharmaceuticals International (VRX)'s Board In Effort To Force Allergan Inc. (AGN) Takeover 9/26/2014 5:53:41 AM
Allergan Inc. (AGN) Issues Statement Regarding Recent Valeant Pharmaceuticals International (VRX) Correspondence 9/25/2014 8:58:58 AM
Valeant Pharmaceuticals International (VRX) Provides Update On Third Quarter Results And Sends Letter To Allergan Inc. (AGN) CEO And Lead Independent Director 9/24/2014 8:40:32 AM
Allergan Inc. (AGN) Must Turn Over Strategic Documents In Takeover Fight: Judge 9/22/2014 5:48:41 PM
12345678910...
//-->